Citius Pharmaceuticals Dirección

Dirección controles de criterios 2/4

El CEO de Citius Pharmaceuticals es Leonard Mazur , nombrado en Mar 2016, tiene una permanencia de 8.67 años. compensación anual total es $1.98M, compuesta por 24% salario y 76% primas, incluidas acciones y opciones de la empresa. posee directamente un 5.67% de las acciones de la empresa, por valor de €3.96M. La antigüedad media del equipo directivo y de la junta directiva es de 3.8 años y 8.5 años, respectivamente.

Información clave

Leonard Mazur

Chief Executive Officer (CEO)

US$2.0m

Compensación total

Porcentaje del salario del CEO	24.0%
Permanencia del CEO	8.7yrs
Participación del CEO	5.7%
Permanencia media de la dirección	3.8yrs
Promedio de permanencia en la Junta Directiva	8.5yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Leonard Mazur en comparación con los beneficios de Citius Pharmaceuticals?
Fecha	Compensación total	Salario	Ingresos de la empresa
Jun 30 2024	n/a	n/a	-US$40m
Mar 31 2024	n/a	n/a	-US$37m
Dec 31 2023	n/a	n/a	-US$39m
Sep 30 2023	US$2m	US$475k	-US$34m
Jun 30 2023	n/a	n/a	-US$31m
Mar 31 2023	n/a	n/a	-US$31m
Dec 31 2022	n/a	n/a	-US$28m
Sep 30 2022	US$1m	US$400k	-US$34m
Jun 30 2022	n/a	n/a	-US$31m
Mar 31 2022	n/a	n/a	-US$29m
Dec 31 2021	n/a	n/a	-US$26m
Sep 30 2021	US$788k	US$348k	-US$25m
Jun 30 2021	n/a	n/a	-US$24m
Mar 31 2021	n/a	n/a	-US$21m
Dec 31 2020	n/a	n/a	-US$21m
Sep 30 2020	US$550k	US$250k	-US$18m
Jun 30 2020	n/a	n/a	-US$17m
Mar 31 2020	n/a	n/a	-US$17m
Dec 31 2019	n/a	n/a	-US$16m
Sep 30 2019	US$473k	US$250k	-US$16m
Jun 30 2019	n/a	n/a	-US$15m
Mar 31 2019	n/a	n/a	-US$12m
Dec 31 2018	n/a	n/a	-US$13m
Sep 30 2018	US$398k	US$250k	-US$13m

Compensación vs. Mercado: La compensación total de Leonard($USD1.98M) está por encima de la media de empresas de tamaño similar en el mercado German ($USD480.14K).

Compensación vs. Ingresos: La compensación de Leonard ha aumentado mientras la empresa no es rentable.

CEO

Leonard Mazur (79 yo)

8.7yrs

Permanencia

US$1,981,113

Compensación

Mr. Leonard L. Mazur is Chairman, Chief Executive Officer & President of Citius Oncology, Inc. from August 12, 2024. Mr. Mazur has been Chief Executive Officer of Citius Pharmaceuticals, Inc. since May 01,...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Leonard Mazur	Co-Founder	8.7yrs	US$1.98m	5.67% € 4.0m
Myron Holubiak	Co-Founder & Executive Vice Chairman	9.1yrs	US$1.59m	1.1% € 769.5k
Myron Czuczman	Executive VP & Chief Medical Officer	4.3yrs	US$1.17m	0% € 0
Jaime Bartushak	Chief Business Officer	7yrs	US$809.00k	0.033% € 23.3k
Gary Talarico	Executive Vice President of Operations	8.7yrs	sin datos	sin datos
Ilanit Allen	Vice President of Investor Relations & Corporate Communications	no data	sin datos	sin datos
Alan Lader	Senior VP and Head of Clinical Operations & Quality Assurance	2.8yrs	sin datos	sin datos
Dhananjay Wadekar	Senior Vice President of Business Strategy	3.8yrs	sin datos	sin datos
Kelly Creighton	Executive Vice President of Chemistry	3yrs	sin datos	sin datos
Nikolas Burlew	Executive Vice President of Quality Assurance	1.8yrs	sin datos	sin datos
Catherine Kessler	Executive Vice President of Regulatory Affairs	1.2yrs	sin datos	sin datos

3.8yrs

Permanencia media

69.5yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de 47N se considera experimentado (3.8 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Leonard Mazur	Co-Founder	10.2yrs	US$1.98m	5.67% € 4.0m
Myron Holubiak	Co-Founder & Executive Vice Chairman	9.1yrs	US$1.59m	1.1% € 769.5k
Dennis McGrath	Independent Director	1.8yrs	US$150.13k	0% € 0
Michael Matthay	ARDS Scientific Advisory Board Member	no data	sin datos	sin datos
Suren Dutia	Independent Director	9.1yrs	US$196.97k	0% € 0
Carol Webb	Independent Director	8.7yrs	US$190.97k	0.0066% € 4.6k
Eugene Holuka	Independent Director	8.4yrs	US$190.97k	0.0013% € 914.4
Issam Raad	Chairman of Scientific Advisory Board	no data	sin datos	sin datos
Mark Rupp	Member of Scientific Advisory Board	no data	sin datos	sin datos
Leonard Mermel	Member of Scientific Advisory Board	6.3yrs	sin datos	sin datos
John Laffey	ARDS Scientific Advisory Board Member	3.4yrs	sin datos	sin datos
Lorraine Ware	ARDS Scientific Advisory Board Member	no data	sin datos	sin datos

8.5yrs

Permanencia media

77yo

Promedio de edad

Junta con experiencia: La junta directiva de 47N se considera experimentada (8.5 años de antigüedad promedio).

Citius Pharmaceuticals Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

Citius Pharmaceuticals, Inc., Annual General Meeting, Mar 12, 2024

Citius Pharmaceuticals, Inc. Announces Changes to its Audit Committee

Citius Pharmaceuticals, Inc. Appoints Dennis M. McGrath to Board of Directors

Citius Pharmaceuticals, Inc., Annual General Meeting, Feb 07, 2023

Insufficient new directors

Insufficient new directors

Recent updates

Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce Promising Preliminary Results of an Investigator-Initiated Phase I Clinical Trial of Pembrolizumab (Keytruda®) and Lymphir™ in Cancer Patients with Recurrent Solid Tumors

Citius Pharmaceuticals, Inc. Provides Non-Compliance Update

New minor risk - Market cap size

Citius Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $50 million.

Citius Pharmaceuticals, Inc. Receives FDA Approval for LYMPHIR Immunotherapy for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma

Forecast breakeven date pushed back to 2026

Citius Pharmaceuticals, Inc. Achieves Primary and Secondary Endpoints in Phase 3 Trial of Mino-Lok Antibiotic Lock Solution

Citius Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $15.000002 million.

Citius Pharmaceuticals, Inc. Announces Addition of City of Hope to UMN's Phase 1 Trial of LYMPHIR in Combination with CAR-T for the Treatment of B-Cell Lymphoma

New major risk - Share price stability

The Nasdaq Stock Market LLC Grants Citius Pharmaceuticals' Request for an Extension through September 9, 2024 to Evidence Compliance with the Bid Price Rule Pursuant to Nasdaq Listing Rule 5550(a)(2)

Forecast breakeven date pushed back to 2026

Citius Pharmaceuticals, Inc. Announces the Resubmission of the Biologics License Application to the U.S. Food and Drug Administration for Lymphir

New minor risk - Market cap size

Citius Pharmaceuticals, Inc., Annual General Meeting, Mar 12, 2024

Citius Pharmaceuticals, Inc. Completes Enrollment in Pivotal Phase 3 Trial of its Mino-Lok Therapeutic to Salvage Catheters

New minor risk - Profitability

Citius Pharmaceuticals, Inc. Announces Publication in Frontiers of Immunology of Positive Results from Solid Tumor Study of LYMPHIR™ in Combination with Checkpoint Inhibitor

Citius Pharmaceuticals, Inc. Announces Changes to its Audit Committee

Citius Pharmaceuticals Receives Non-Compliance Notice from Nasdaq Stock Market

Citius Pharmaceuticals Receives Non-Compliance Notice from Nasdaq Stock Market

Citius Pharmaceuticals, Inc. Receives Regulatory Guidance from the U.S. Food and Drug Administration Regarding the Planned Resubmission of the BLA for LYMPHIR

Citius Pharmaceuticals, Inc. Reaches 92 Event Milestone in Mino-Lok Phase 3 Trial

Citius Pharmaceuticals, Inc. Receives a Complete Response Letter from the U.S. Food and Drug Administration (FDA) for LYMPHIR™ (Denileukin Diftitox) for the Treatment of Patients with Relapsed or Refractory Cutaneous T-Cell Lymphoma

Citius Pharmaceuticals, Inc. Announces Positive Results from the Phase 2b Study of Halo-Lido (CITI-002) for the Treatment of Hemorrhoids

Forecast breakeven date pushed back to 2025

Forecast breakeven date pushed back to 2025

Citius Pharmaceuticals, Inc. Appoints Dennis M. McGrath to Board of Directors

Citius Pharmaceuticals, Inc., Annual General Meeting, Feb 07, 2023

Citius Pharmaceuticals, Inc. Announces U.S. Food and Drug Administration Acceptance of Biologics License Application of Denileukin Diftitox for Treatment of Patients with Persistent or Recurrent Cutaneous T-Cell Lymphoma

Insufficient new directors

Citius Pharmaceuticals, Inc. Submits Biologics License Application to the U.S. Food and Drug Administration for Denileukin Diftitox for the Treatment of Patients with Persistent or Recurrent Cutaneous T-Cell Lymphoma

Citius Pharmaceuticals, Inc. Holds Pre-BLA Meeting with the FDA for I/ONTAK for the Treatment of Cutaneous T-Cell Lymphoma

Insufficient new directors

Citius Pharmaceuticals, Inc. Enrolls First Patient in Phase 2B Study of Halo-Lido for the Prescription Treatment of Hemorrhoids

Citius Pharmaceuticals, Inc. Announces Executive Changes

Forecast breakeven date pushed back to 2024

Citius Pharmaceuticals Reports Topline Data from the Pivotal Phase 3 Study of Cancer Immunotherapy I/Ontak (E7777)

Citius Pharmaceuticals Announces FDA Acceptance of IND Application for its Phase 2b Study of Halo-Lido for the Prescription Treatment of Hemorrhoids

Forecast breakeven date moved forward to 2023

Citius Pharmaceuticals, Inc. Completes Enrollment in the Pivotal Phase 3 Study of its Cancer Immunotherapy I/ONTAK for the Treatment of Cutaneous T-Cell Lymphoma

Citius Pharmaceuticals Acquires Dr. Reddy's Laboratories' License for Late-Phase 3 Oncology Immunotherapy (E7777) for the Treatment of Cutaneous T-Cell Lymphoma and other Cancer Indications

Citius Pharmaceuticals, Inc. (NasdaqCM:CTXR) agreed to acquire Rights and Certain Related Assets of Dr. Reddy's Laboratories Limited (BSE:500124) for approximately $150 million.

Citius Pharmaceuticals, Inc. Announces Positive Recommendation by Independent Data Monitoring Committee to Continue the Mino-Lok® Phase 3 Trial as Planned

Citius Pharmaceuticals Achieves Next Interim Analysis Milestone in its Mino-Lok® Phase 3 Trial

Citius Pharmaceuticals, Inc. Reports Strong Clinical Community Engagement During Mino-Lok Phase 3 Trial-Related Webinar

Análisis de compensación del CEO

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad